CSPG4 and melanoma: In this study we first reported the intense preclinical antitumor activity of CSPG4-CAR.CIK against melanoma, confirming that such effect stands even when target tumors display low or defective expression of HLA class I molecules, a condition associated with resistance to checkpoint inhibitors in melanoma patients.